Skip to main content

Suzanne E Wardell

Assistant Research Professor of Pharmacology & Cancer Biology
Pharmacology & Cancer Biology
Box 3813 Med Ctr, Durham, NC 27710
LSRC. C-248, Durham, NC 27710

Selected Grants


Ferroptosis and Ferroptotic Stress in Maladaptive Renal Repair - R01

ResearchCollaborator · Awarded by National Institute of Diabetes and Digestive and Kidney Diseases · 2023 - 2028

Manipulating normal estrogen physiology as a therapeutic approach in cancer

ResearchAssistant Research Professor · Awarded by National Institutes of Health · 2023 - 2028

Elucidation of the mechanisms by which cells recognize and respond to different levels of androgens

ResearchAssistant Research Professor · Awarded by National Institutes of Health · 2022 - 2027

Evaluation of the efficacy of a combined regimen including an ER targeted therapy and ICB

ResearchPrincipal Investigator · Awarded by Sermonix Pharmaceuticals · 2023 - 2024

Cancer cell intrinsic and extrinsic actions of steroid hormones in breast tumors

ResearchAssistant Research Professor · Awarded by Department of Defense · 2018 - 2023

Ferroptosis and Ferroptotic Stress in Maladaptive Renal Repair - R01

ResearchCollaborator · Awarded by National Institute of Diabetes and Digestive and Kidney Diseases · 2023 - 2028

Manipulating normal estrogen physiology as a therapeutic approach in cancer

ResearchAssistant Research Professor · Awarded by National Institutes of Health · 2023 - 2028

Elucidation of the mechanisms by which cells recognize and respond to different levels of androgens

ResearchAssistant Research Professor · Awarded by National Institutes of Health · 2022 - 2027

Evaluation of the efficacy of a combined regimen including an ER targeted therapy and ICB

ResearchPrincipal Investigator · Awarded by Sermonix Pharmaceuticals · 2023 - 2024

Cancer cell intrinsic and extrinsic actions of steroid hormones in breast tumors

ResearchAssistant Research Professor · Awarded by Department of Defense · 2018 - 2023

HOXB13 as a therapeutic target in prostate cancer

ResearchAssistant Research Professor · Awarded by Prostate Cancer Foundation · 2020 - 2023

Regulatory principles of the Warburg Effect

ResearchCollaborator · Awarded by American Cancer Society, Inc. · 2017 - 2022

Evaluation of SGK as a therapeutic target in models of breast and prostate cancer

ResearchPrincipal Investigator · Awarded by LQT Therapeutics · 2021 - 2022

Evaluation of estrogen receptor as a therapeutic target in melanoma, lung and colorectal cancer models

ResearchPrincipal Investigator · Awarded by Zentalis Pharmaceuticals · 2020 - 2022

Identification of Novel Targets in Treatment Resistant Prostate Cancer

ResearchAssistant Research Professor · Awarded by Celgene Corporation · 2017 - 2022

Role of ER RNA Binding Domain in Breast Cancer

ResearchAssistant Research Professor · Awarded by Ribometrix LLC · 2022 - 2022

Evaluation of novel CDK4/6/9 inhibitors in triple negative breast cancer

ResearchPrincipal Investigator · Awarded by SPV Therapeutics, Inc · 2020 - 2020

Developing in vivo active probes for CAMKK2 to treat cancer

ResearchAssistant Research Professor · Awarded by University of North Carolina - Chapel Hill · 2017 - 2020

Targeting precursor neural (N)-cadherin to eliminate chemotherapy-resistant triple-negative breast tumor cells

ResearchCo Investigator · Awarded by Department of Defense · 2017 - 2020

Targeting differential apoptosis regulation in triple negative breast cancer

ResearchAssistant Research Professor · Awarded by Department of Defense · 2016 - 2019

Evaluation of G1 antiestrogens in models of estrogen action

ResearchAssistant Research Professor · Awarded by G1 Therapeutics Inc. · 2018 - 2019

Targeting the synthetic essential kinases of breast cancers

ResearchResearch Scientist · Awarded by Department of Defense · 2015 - 2018

Evaluating the efficacy of targeting the AGR2 axis in breast and prostate cancer

ResearchPrincipal Investigator · Awarded by Viba Therapeutics · 2017 - 2018

Evaluation of the SERD XR5-28 in models of estrogen action

ResearchAssistant Research Professor · Awarded by G1 Therapeutics Inc. · 2016 - 2017

Evaluation of G1T38 and SERD XR5-28 in hormone refractory breast cancer

ResearchAssistant Research Professor · Awarded by G1 Therapeutics Inc. · 2016 - 2017

Determination of the antiandrogenic properties of VT-464 in models of CRPC

ResearchPrincipal Investigator · Awarded by Innocrin Pharmaceutical, Inc. · 2016 - 2017

Evaluation of the therapeutic potential of combining VT464 and G1T38 in treatment-resistant prostate and breast cancer models

ResearchAssistant Research Professor · Awarded by Innocrin Pharmaceutical, Inc. · 2016 - 2017

Targeting the CDK 4/6 axis in Castration Resistant Prostate Cancer

ResearchResearch Scientist · Awarded by G1 Therapeutics Inc. · 2015 - 2016

Evaluation of VT-464 in AR positive and ER positive breast cancer models

ResearchResearch Scientist · Awarded by Innocrin Pharmaceutical, Inc. · 2015 - 2016

Androgen receptor degradation as a therapeutic modality in castrate resistant prostate cancer

ResearchResearch Scientist · Awarded by Arvinas Inc. · 2015 - 2015

Determination of the antiandrogenic properties of VT-464, a novel CYP17 lyase inhibitor

ResearchResearch Scientist · Awarded by Viamet Pharmaceuticals · 2014 - 2015

Molecular pharmacology of bazedoxifene and pipendoxifene in breast cancer

ResearchResearch Scientist · Awarded by Pfizer, Inc. · 2013 - 2014

External Relationships


  • Lumanity
  • Radius Health
  • SPV Therapeutics, Inc.
  • Zentalis Pharmaceuticals (formerly Zeno Pharma)

This faculty member (or a member of their immediate family) has reported outside activities with the companies, institutions, or organizations listed above. This information is available to institutional leadership and, when appropriate, management plans are in place to address potential conflicts of interest.